Management and Treatment of Diabetic Macular Edema after Protocol T
The live program has concluded.
If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.
Overview
The release of the 1-year results of the DRCRnet's Protocol T study were of great interest to the retina community. Some physicians saw the data as proof positive that certain disease indicators called for particular therapeutic approaches for DME patients. Others noted that although the data were interesting, 2 years of data were required to fully assess the efficacy of the tested anti-VEGF agents. Now that the 2-year data are released, how should retina specialists apply this new information in the clinic? Join our panel of research experts as they parse the 2-year Protocol T data, enabling you to provide the most effective care for your DME patients.This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc. Learning Objectives
Upon completion of this activity, you will be better able to: - Assess clinical studies involving new approaches to treat DME, with particular attention to the DRCR.net’s Protocol T
- Differentiate existing DME intravitreal therapy options from recent primary and secondary treatments
- Evaluate treatment options and develop criterion/criteria on when to initiate or alter therapy
- Discuss case scenarios and apply data from recent clinical studies to better manage patients with DME
Accreditation
Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians. Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Faculty and Disclosures
DISCLOSURE POLICY
Rishi P. Singh, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon, Inc; Genentech, Inc; Regeneron Pharmaceuticals, Inc; and ThromboGenics NV. Contracted Research: Alcon, Inc; Genentech, Inc; Regeneron Pharmaceuticals, Inc. Mandeep Brar, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Janssen Pharmaceutica and Regeneron Pharmaceuticals, Inc. Mark Dunbar, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals, Inc. John Kitchens, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Genentech, Inc.; Synergetics USA Inc.; and ThromboGenics NV. Cheryl Cavanaugh, MS; Michelle Dalton; and Melanie Lawler, PhD have no relevant commercial interests to disclose.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC and Regeneron Pharmaceuticals, Inc. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Yewlin E. Chee, MD
Camila Ventura MD, PhD
Edward Wood, MD
Tony Capone Jr, MD
Katherine E. Talcott, MD
Nassim Abreu, MD
- CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 creditDeepak Sambhara, MD
Katherine E. Talcott, MD
Roger A. Goldberg, MD, MBA
